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Abstract 
Hexaminolevulinate blue light cystoscopy (HAL-BLC) represents an increasingly acknowledged method in 
bladder cancer diagnostic. We aimed to evaluate the importance of this procedure in cases of non-invasive bladder 
tumors (NIBT), to compare it with standard white light cystoscopy (WLC), and to establish the efficiency of blue light 
transurethral bladder resection (BL-TURB). 
Between December 2007 and December 2008, WLC and BLC were performed in 70 cases. WL-TURB was 
performed for all lesions visible in WL, and BL-TURB for those only detected in BL. Patients diagnosed with NIBT 
were followed-up after an average period of 5 months (between 18 and 22 weeks) by WLC and BLC. The control group 
included the same number of consecutive cases of NIBT, which underwent only WLC and WL-TURB, as well as the 
same follow-up protocol as the study group.  
WLC correctly identified 115 tumors, and BLC, 157 tumors. The detection rate was 68.8% for WLC, with a 
9.4%  rate  of  false-positive  results,  and  94%  for  BLC,  with  a  14.6%  rate  of  false-positive  results.  The  diagnostic 
accuracy in CIS lesions was 57.3% for WLC and 95% for BLC, while in pTa tumors; it was 68.8% for WLC and 94% 
for BLC. 62 cases of the study group diagnosed with NIBT emphasized a recurrence rate of 6.4% after 5 months. The 
control group described a recurrence rate of 24.2%.  
HAL  fluorescence  cystoscopy  is  a  valuable  diagnostic  method  for  patients  with  NIBT,  with  considerably 
improved accuracy by comparison to WLC, and a significant impact upon the short-term recurrence rate. 
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Introduction 
 
Bladder  cancer  represents  a  common 
malignancy, with a severely high recurrence rate. 
Despite the fact that WLC is still regarded as the 
gold-standard  diagnostic  method  for  NIBT  [1], 
small  papillary  (Ta,  T1)  and  especially  flat 
(carcinoma in situ – CIS) urothelial lesions can be 
easily  overlooked,  thus  leading  to  a  significant 
increase of the recurrence rate [2]. 
Therefore,  while  searching  for  a  more 
sensitive  diagnostic  tool,  the  photodynamic 
diagnosis (PDD) emerged as a promising solution. 
The  aminolevulinic  acid  (ALA)  was 
among  the  first  products  used  for  PDD.  After 
introducing  its  improved  ester,  the  hexyl 
aminolevulinate (HAL – Hexvix
®), PDD acquired 
a substantial acknowledgement in practical use. 
The  EAU  Guidelines  state  that 
fluorescence cystoscopy, performed in blue light 
(BL) and using a porphyrin-based photosensitizer, 
may help discovering suspicious areas, not visible 
in white light (WL) [1].  
Moreover, BL-TURB can be expected to 
improve the quality of the endoscopic treatment, 
allowing a more complete resection of the existing 
tumors. 
In  this  study,  we  aimed  to  establish  the 
value of HAL-BLC as complementary diagnostic 
tool  in  patients  suspected  of  bladder  cancer,  to 
compare  it  with  standard  cystoscopy,  and  to 
clarify  the  advantages  of  BL-TURB  over  the 
standard  resection.  We  also  attempted  to 
determine  the  influence  of  this  diagnostic  and 
treatment method over the short-term recurrence 
rate in such cases. 
 
Materials and Methods 
 
Between  December  2007  and  December 
2008,  70  consecutive  cases  (49  men  and  21 
women), with a mean age of 66 years (range 34 to Journal of Medicine and Life  Vol. 2, No.2, April-June 2009  
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83),  have  been  admitted  and  investigated  for 
hematuria and/or positive urinary cytology.  
A  standard  investigative  protocol  which 
included general clinical examination, blood tests, 
urine  culture,  abdominal  ultrasonography,  IVP 
and eventually a CT scan was applied in all cases. 
The  exclusion  criteria  included  massive 
hematuria  (BL  being  highly  absorbed  by  blood 
and  clots),  moderate  to  severe  leucocyturia,  and 
prior  history  of  bladder  cancer  or  imagistic 
evidence of upper urinary tract disease. 
HAL  bladder  instillation  (100mg 
dissolved  in  50mL  phosphate  buffer  solution, 
8mmol)  was  performed  using  a  14Ch  bladder 
catheter, after complete voiding, 1 to 2 hours prior 
to cystoscopy (an average instillation time of 90 
minutes).  
The Storz D-light-C system with a xenon 
arc lamp as source was used in all cases. 
The first stage consisted of careful WLC, 
resulting  in  a  bladder  map  of  the  suspicious 
lesions,  followed  by  BLC,  which  described  a 
specific map of all distinctive fluorescent areas. 
WL-TURB  was  performed  for  all  the 
suspected lesions identified by WLC, while BL-
TURB was applied for tumors discovered only by 
BLC. All suspicious areas were entirely resected. 
The  histological  analysis  emphasized  a 
„pathological” bladder chart for each patient. We 
compared  the  3  bladder  maps  in  order  to 
determine  the  accuracy  of  these  diagnostic 
methods.  
Patients  diagnosed  with  NIBT  were 
followed  after  an  average  period  of  5  months 
(between  18  and  22  weeks)  by  both  WLC  and 
BLC,  and  underwent  WL  and  eventually  BL-
TURB for all suspicious areas.  
The  control  group  included  the  same 
number  of  consecutive  patients  with  NIBT, 
initially  diagnosed  only  by  WLC,  which 
underwent  WL-TURB,  as  well  as  the  same 
intravesical therapy and follow-up protocol as the 
study group. The recurrence rates were compared 
between the 2 groups. 
 
Results 
 
The  cystoscopic  and  pathological  results 
described 4 different groups of patients. 
Group  I  consisted  of  patients  with 
identical  bladder  maps  according  to  WLC  and 
BLC, and entirely confirmed by the pathological 
examination.  This  group  included  31  cases 
(44.2%)  with  73  tumors  identified  by  both 
diagnostic tools (23 CIS, 32 pTa, 15 pT1 and 3 
pT2) (Fig. 1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Group II was represented by 26 patients 
(37.1%) diagnosed with bladder cancer by WLC, 
and  in  which  BLC  showed  at  least  one 
supplementary  bladder  tumor.  Overall,  WLC 
described  48  suspicious  lesions,  42  being 
pathologically confirmed (12 CIS, 16 pTa, 12 pT1 
and 2 pT2). BLC identified 43 additional lesions, 
33  of  which  being  confirmed  by  pathology  (16 
CIS and 17 pTa) (Fig. 2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1 pT1G1 urothelial bladder tumor visible both 
in WLC (left) and BLC (right) 
 
Fig. 2 Distinctive fluorescent aspect of a pTaG1 
tumor, not visible in white light 
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In  total,  BLC  described  65  tumors  (25 
CIS,  26  pTa,  12  pT1  and  2  pT2),  while  17 
fluorescent  lesions  had  no  pathological 
confirmation. In 5 cases, 10 malignancies (3 CIS 
and  7  pTa)  described  by  WLC  presented  no 
fluorescence in BLC (Fig. 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Group III consisted of 10 patients (14.2%) 
tumor-free in WL, but in which BLC described 29 
fluorescent areas, 19 being confirmed by pathology as 
malignant (10 CIS and 9 pTa) (Fig. 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Group IV included 3 cases (4.2%) with 6 
apparently malignant lesions according to WLC, 
no  fluorescence  in  BLC  and  no  pathological 
confirmation (Fig. 5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In total, a number of 167 tumors (61 CIS, 74 
pTa, 27 pT1 and 5 pT2) were diagnosed in 67 cases 
(95.7%).  BLC  provided  additional  diagnostic 
information  in  36  patients  (51.4%),  describing  52 
supplementary tumors (26 CIS and 26 pTa – 31.1%) 
by  comparison  to  WLC,  which  only  found  10 
additional lesions (3 CIS and 7 pTa – 5.9%).  
The  sensitivity  of  WLC  was  68.8%  (115 
correctly diagnosed tumors – 35 CIS, 48 pTa, 27 pT1, 
5 pT2), and the rate of false-positive results was 9.4% 
(12 negative biopsies).  
The  diagnostic  accuracy  of  BLC  was  94% 
(157 confirmed tumors – 58 CIS, 67 pTa, 27 pT1, 5 
pT2), while the rate of false-positive results was 14.6% 
(27 negative biopsies).  
The  most  relevant  differences  in  detection  rates 
occurred for CIS lesions, 95% of them being correctly 
diagnosed by BLC, and only 57.3% by WLC (Fig. 6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3 pTaG1 tumor, visible in white light, with no 
fluorescence in blue light 
 
Fig. 4 CIS lesion, visible only in blue light 
 
Fig. 5 Suspicious flat lesion in white light, with no 
fluorescence in blue light and no pathological 
confirmation 
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Differences  remained  significant 
concerning  the  pTa  tumors,  for  which  WLC 
emphasized a diagnostic accuracy of 64.8%, and 
BLC, of 90.5%. 
In  7  of  the  67  cases  of  bladder  cancer 
(10.4%), malignant lesions diagnosed by WLC (1 
pTa, 5 pT1  and 1 pT2 tumor) emphasized after 
WL-TURB  fluorescent  positive  margins  in  blue 
light, confirmed by pathology (Fig. 7).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
There  were  no  specific  complications 
related to HAL-BLC.  
After  an  average  period  of  5  months, 
WLC,  BLC  and  eventually  re-TURB  were 
performed for the 62 patients of the study group 
initially diagnosed with NIBT, as well as for the 
similar number of patients included in the control 
group. 
The  tumor  recurrence  rate  was  6.4%  (4 
cases with 3 CIS and 3 pTa tumors) for the study 
group  and  significantly  higher,  24.2% (15  cases 
with 12 CIS and 10 pTa), for the control group. 
 
Commentaries 
 
The basis of HAL-BLC is represented by 
the  preferential  accumulation  of  the  photoactive 
porphyrin in the neoplastic tissue, resulting in red 
fluorescence emitting tumors [3]. By comparison 
to ALA, HAL provides the benefits of increased 
selectivity,  brighter  fluorescence  and  shorter 
instillation time [4,5,6]. 
The  prostate  urethra,  bladder  neck, 
ureteral orifices, as well as the tangential view of 
the  bladder  mucosa  may  create  aspects  of  false 
fluorescence,  and  therefore  the  bladder  must  be 
fully  distended  and  lesions  should  be  directly 
illuminated. Lesions in which fluorescence fades 
by pressing the concerned area with the resection 
loop  are  usually  benign  and  resection  is 
unnecessary. 
Bladder  inflammation  may  determine 
increased  fluorescence  of  the  mucosa  and 
consequently,  false-positive  results.  BLC  should 
not be performed any sooner than 6 weeks after 
BCG  (Bacillus  Calmette-Guerin)  intravesical 
instillations.  Our  protocol  included  a  minimum 
period  of  2  months  between  the  last  instillation 
and the follow-up cystoscopic control.  
On the other hand, BL is highly absorbed 
by  blood  and  clots.  Therefore,  resection  related 
bleeding  may  result  in  poor  visualization  and 
reduced diagnostic accuracy.  
According  to  a  study  performed  by 
Jichlinski  et  al.,  BLC  is  well  tolerated,  with  no 
side  effects  related  to  HAL  bladder  instillation 
[7]. 
The diagnostic accuracy in our series was 
significantly  improved  for  BLC  (94%)  by 
comparison to WLC (68.8%). The literature data 
mention  quite  resembling  results,  specifically 
97% versus 78% [4], and 96% versus 77% [8].   
Groups II and III clearly emphasized the 
advantages provided by this type of cystoscopy. It 
is  highly  significant  that in  51.4%  of the  cases, 
HAL-BLC  diagnosed  at  least  one  additional 
bladder tumor. A European phase III multicenter 
study  on  211  patients  obtained  a  similar  rate, 
describing supplementary tumors in 55% of cases 
[4].   
More so, it is remarkable that 14.2% of 
our patients were diagnosed with bladder cancer 
only by BLC and declared cancer-free by WLC 
(Fig. 8). 
Fig. 6 CIS lesion not visible in white light but 
fluorescent in blue light 
 
Fig. 7 Fluorescent margin of a pT1G2 tumor after 
WL-TURB, confirmed by pathology 
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Our  study  emphasized  a  CIS  detection 
rate  of  95%  for  BLC,  significantly  superior  to 
WLC,  which  only  diagnosed  57.3%  of  the  CIS 
lesions (Fig. 9).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fradet et al. obtained comparable results 
in an American phase III multicenter study on 298 
patients, which described a CIS detection rate of 
92% for BLC and 68% for WLC, respectively [3]. 
Schmidbauer et al. [4] determined results closer to 
ours,  showing  a  CIS  detection  rate  of  97%  for 
BLC, and of 58% for WLC. 
We  emphasized  a  9.4%  rate  of  false-
positive results for WLC, and of 14.6% for BLC 
(Fig. 10).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The study by Schmidbauer et al. showed 
similar data (10% for WLC versus 13% by BLC) 
[4]. However, Grossman et al. [9] and Jocham et 
al. [8] presented higher false-positive rates (39% 
versus 31% and 37% versus 26%, respectively). 
It was proved that recurrence at any site 
of  the  bladder  during  the  first  follow-up 
cystoscopy after TUR constitutes one of the most 
important  prognostic  factors  for  time  to 
progression.  Consequently,  PDD  might  be  most 
useful in patients with primary tumors [10]. 
It  is  quite  obvious  that  tumors  shortly 
diagnosed  after  TURB  are  mostly  lesions 
overlooked  during  the  primary  procedure  rather 
than  newly  developed  malignancies.  This  is  the 
rationale for trying to improve the recurrence rate 
and  prognostic  of  the  patients  by  superior 
diagnostic accuracy. 
Among our cases, the recurrence rate at 5 
months was 6.4% for the BLC group and 24.2% 
for the WLC group. 
Similarly,  the  comparative  analysis 
performed by Denziger et al. on 191 cases with 
NIBT,  diagnosed  either  by  WLC  or  BLC, 
described a residual tumors’ rate at 6 weeks after 
primary TURB of 25.2% and 4.5%, respectively. 
Fig. 8 CIS lesion diagnosed only by blue light 
cystoscopy 
 
Fig. 9 CIS lesion omitted by white light 
 
Fig. 10 Suspicious lesion in white light, with no 
fluorescence and no pathological confirmation Journal of Medicine and Life  Vol. 2, No.2, April-June 2009  
  190 
© 2009, Carol Davila University Foundation 
The recurrence rates among these patients after an 
average follow-up period of 86 months were 44% 
in the WLC arm versus 16% in the BLC arm [11]. 
Daniltcenko  et  al.  emphasized  the  fact 
that differences between the recurrence rates tend 
to decrease in time. At 2, 12, 36 and 60 months 
from  the  initial  TURB,  these  rates  were  41%, 
61%, 73% and 75% in the WLC arm versus 16%, 
43%, 59% and 59% in the BLC arm [12]. In the 
future, this tendency should be evaluated during 
our medium and long-term follow-up.  
Colombo  states  that  the  most  important 
clinical impact of PDD was determined in cases 
of CIS, pT1G3 or multiple tumors. The method 
provides  advantages  concerning  TURB  efficacy 
and postoperative follow-up [13]. 
Burger et al. analyzed the treatment costs 
in bladder cancer, focusing on German patients. 
After an elaborate financial analysis, the authors 
concluded that PDD implied savings of 168 Euro  
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reduced  recurrence  rate  during  the  short-term 
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